|
|
Post by selluwud on Feb 29, 2016 14:23:20 GMT
New thread for those investing in Astellas. Even though they are a large pharmacy biotech, having bought Ocata now definitely puts them in the regenerative medicine business. Lots of action this morning in premarket for this ADR format trading on the Pinks.
|
|
|
|
Post by selluwud on Mar 1, 2016 14:39:12 GMT
|
|
|
|
Post by selluwud on Mar 3, 2016 13:31:52 GMT
Notice the CEO responsibilities, Yoshihiko Hatanaka is directly responsible for OCATA. Not sure if the "MS" letters are part of the Ocata verbiage or not. Interesting. Maybe I should read first write second. MS stands for "Marketing Strategy" www.astellas.com/en/corporate/news/pdf/160301_1_Eg.pdf |
|
